Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alexey Aleshin"'
Autor:
Zeynep Eroglu, Joe Ensor, Meenakshi Malhotra, Paul Billings, Angel Rodriguez, Alexey Aleshin, Ling Gao, Sarah Sawyer, Pashtoon Murtaza Kasi, Sascha Ellers, George Ansstas, Michael Krainock, Sakti Chakrabarti, Andrew Poklepovic, Minu Maninder
Publikováno v:
BMJ Open, Vol 12, Iss 5 (2022)
Externí odkaz:
https://doaj.org/article/1710b670c7d04923bb1d5cd95028e149
Autor:
Meenakshi Malhotra, Alexey Aleshin, Pashtoon Murtaza Kasi, Allyson Koyen Malashevich, Griffin Budde, Michael Krainock, Vasily N Aushev, Perry Olshan, Paul R Billings
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/313a4178cc364854b38439068ed47929
Autor:
David Goldstein, Anna Spreafico, Ilan Weinreb, Trevor J. Pugh, Scott V Bratman, Bayardo Perez-Ordonez, Aaron R Hansen, Lillian Siu, Antony Tin, Alexey Aleshin, Amy Prawira, Jonathan Irish, John de Almeida, Douglas Chepeha, Stephen Smith, Marc Oliva, Daniel V Araujo, J. Javier Diaz-Mejia, Peter Olson, Tina Shek, Andrew Hope, Dax Torti, Jeffrey P. Bruce, Ben X. Wang, Anthony Fortuna, Hirak Der-Torossian, Ronald Shazer, Nickolas Attanasio, Qingyan Au, Jordan Feeney, Himanshu Sethi, Isan Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/0c91b22ec6d04b31bb0d153a425dbaed
Autor:
Georges Azzi, Shifra Krinshpun, Antony Tin, Allyson Malashevich, Meenakshi Malhotra, Paul Billings, Angel Rodriguez, Alexey Aleshin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d1ac0858084e49ef9a8c59288afe203f
Autor:
Pashtoon Murtaza Kasi, Griffin Budde, Michael Krainock, Vasily N Aushev, Allyson Koyen Malashevich, Meenakshi Malhotra, Perry Olshan, Paul R Billings, Alexey Aleshin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treat
Autor:
Antony Tin, Lillian L. Siu, Nickolas Attanasio, David P. Goldstein, Tina Shek, Bayardo Perez-Ordonez, J. Javier Díaz-Mejía, Ronald Shazer, Anna Spreafico, Douglas B. Chepeha, Ben X Wang, Ilan Weinreb, Hirak Der-Torossian, Andrew Hope, Aaron R. Hansen, Daniel Vilarim Araujo, Qingyan Au, Amy Prawira, John R. de Almeida, Alexey Aleshin, Jordan Feeney, Marc Oliva, Peter Olson, Stephen M. Smith, Jonathan C. Irish, Jeff Bruce, Anthony Fortuna, Himanshu Sethi, Isan Chen, Trevor J. Pugh, Dax Torti, Scott V. Bratman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic ant